Patents Examined by Kahsay Habte
  • Patent number: 11512095
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 29, 2022
    Assignees: The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology Limited
    Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
  • Patent number: 11512090
    Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: November 29, 2022
    Assignee: Pipeline Therapeutics, Inc.
    Inventors: Yifeng Xiong, Thomas Schrader, Austin Chen, Jeffrey Roger Roppe, Jill Melissa Baccei, Yalda Bravo
  • Patent number: 11512097
    Abstract: The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula I wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: November 29, 2022
    Assignee: AMGEN INC.
    Inventors: Jennifer R. Allen, Michela Beltrani, Matthew P. Bourbeau, Teodora P. Damyanova, Iain Lingard, Ana E. Minatti, Paolo Vincetti
  • Patent number: 11512058
    Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: November 29, 2022
    Assignee: Nocion Therapeutics, Inc.
    Inventors: Bridget McCarthy Cole, James Lamond Ellis
  • Patent number: 11498927
    Abstract: The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 15, 2022
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Bing Zhou, Wei Tang, Xiangbo Yang, Huimin Lu, Mengying Gao, Yaxi Yang, Huijin Feng
  • Patent number: 11498926
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: November 15, 2022
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
  • Patent number: 11498930
    Abstract: Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.
    Type: Grant
    Filed: February 3, 2019
    Date of Patent: November 15, 2022
    Assignee: BLUERAY THERAPEUTICS (SHANGHAI) CO., LTD
    Inventors: Bin Zou, Xianlei Fu, Rui Zhang, Shichao Ma, Shuaijie Xu, Wencheng Fu, Lanzhen Liu
  • Patent number: 11492350
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: November 8, 2022
    Assignee: Tango Therapeutics, Inc.
    Inventors: Kevin M. Cottrell, John P. Maxwell
  • Patent number: 11492348
    Abstract: The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or inhibiting the PI3K-AKT-MTOR pathway, and methods of treating diseases that are associated with autophagy or the PI3K-AKT-MTOR pathway.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: November 8, 2022
    Assignee: Neuropore Therapies, Inc.
    Inventors: Emily M. Stocking, Wolfgang J. Wrasidlo
  • Patent number: 11479541
    Abstract: Provided is an acid addition salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine selected from a tartrate salt, a phosphate salt, and a fumarate salt. Also provided are pharmaceutical compositions comprising an acid addition salt disclosed herein and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: October 25, 2022
    Assignee: Pioneura Corporation
    Inventors: Harris A. Gelbard, John M. McCall, Jesse Damsker, Arthur Romero
  • Patent number: 11472798
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: October 18, 2022
    Assignee: MISSION THERAPEUTICS LTD
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Patent number: 11472825
    Abstract: The present invention relates to a real-time fluorescence imaging sensor for measuring glutathione in cell organelles and a method for fabricating the same. More specifically, the present invention relates to a novel compound for measuring glutathione in cell organelles, a method for preparing the novel compound, a real-time fluorescence imaging sensor for measuring glutathione in cell organelles, which comprises the novel compound, a method for fabricating the imaging sensor, and a method of measuring glutathione in cell organelles by use of the imaging sensor. When the composition comprising the compound according to the present invention is used, it can measure the antioxidant activity of the organelle mitochondria or Golgi apparatus in living cells, particularly stem cells, and can screen highly active stem cells based on the results obtained by measuring the antioxidant activity of the cell organelle.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: October 18, 2022
    Assignee: CELL2IN, INC.
    Inventors: Heun Soo Kang, Hye Mi Kim, Ji Eun Song, Myoung Jin Kim, Ki Hang Choi
  • Patent number: 11466029
    Abstract: The invention provides compounds that may inhibit influenza virus replication, and are accordingly useful for treatment of viral infections caused by influenza virus. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent viral infections caused by influenza virus.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: October 11, 2022
    Assignee: NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.
    Inventors: Xiaolin Hao, Jinfu Yang
  • Patent number: 11465996
    Abstract: The present disclosure provides compounds which are useful for a number of catalytic transformations of organic molecules, non-limiting examples including dehydrogenation of alkanes. The present disclosure further relates to methods of preparing the compounds of the present disclosure.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: October 11, 2022
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Alan S. Goldman, Thomas R. Dugan
  • Patent number: 11466034
    Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: October 11, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd.
    Inventors: Yan Xu, Xiaofeng Xu, Jiabing Wang, Lieming Ding
  • Patent number: 11465997
    Abstract: In one aspect, the present disclosure provides disorazole analogs of the formula: Formula (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 11, 2022
    Assignee: William Marsh Rice University
    Inventors: Kyriacos C. Nicolaou, Gabriel Bellavance, Marek Buchman, Kiran Kumar Pulukuri, Stephan Rigol
  • Patent number: 11466013
    Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: October 11, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd
    Inventors: Hao Wu, Wei Gu, Xiaojing Tang, Wei Wang, Bo Zhan, Dongjie Feng, Yongxin Ke, Zhongyan Chen, Yifei Shen, Wenmao Wu, Xintao Zhao, Hong Lan, Jiabing Wang, Lieming Ding
  • Patent number: 11459337
    Abstract: Disclosed in the present invention are an IRAK4 inhibitor, and an application thereof in preparation of a drug for treating IRAK4-related diseases. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 4, 2022
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Inc.
    Inventors: Yang Zhang, Jianfei Wang, Haizhong Tan, Jie Li, Jian Li, Shuhui Chen
  • Patent number: 11459323
    Abstract: Disclosed are a class of new monocyclic ?-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated with bacterial infection. Specifically disclosed are the compounds as shown in formula (I?) and formula (II?), isomers thereof or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 4, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lianghu Gu, Wei Luo, Zhigang Huang, Charles Z. Ding, Cheng Li, Shuhui Chen
  • Patent number: 11453683
    Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: September 27, 2022
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton